---
title: "Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis"
description: "Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis"
---

[PathAI Publications ](https://www.pathai.com/publications)

# [Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis](https://www.pathai.com/publications/clinical-trial-effects-of-pegozafermin-on-the-liver-and-on-metabolic-comorbidities-in-subjects-with-biopsy-confirmed-nonalcoholic-steatohepatitis)

 Written by [Admin](https://www.pathai.com/publications/author/admin) | Aug 31, 2023 4:00:00 AM

## Abstract

Background: An approved therapy for nonalcoholic steatohepatitis (NASH) and fibrosis remains a major unmet medical need.

Aim: To investigate the histological and metabolic benefits of pegozafermin, a glyco-PEGylated FGF21 analogue, in subjects with biopsy-confirmed NASH.

Methods: This proof-of-concept, open-label, single-cohort study, part 2 of a phase 1b/2a clinical trial, was conducted at 16 centres in the United States. Adults (age 21–75 years) with NASH (stage 2 or 3 fibrosis, NAS≥4) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) ≥8% received subcutaneous pegozafermin 27 mg once weekly for 20 weeks. Primary outcomes were improvements in liver histology, and safety and tolerability. Results: Of 20 enrolled subjects, 19 completed the study. Twelve subjects (63%) met the primary endpoint of ≥2-point improvement in NAFLD activity score with ≥1-point improvement in ballooning or lobular inflammation and no worsening of fibrosis. Improvement of fibrosis without worsening of NASH was observed in 26% of subjects, and NASH resolution without worsening of fibrosis in 32%. Least-squares mean relative change from baseline in MRI-PDFF was −64.7% (95% CI: −71.7, −57.7; p< 0.0001). Significant improvements from baseline were also seen in serum aminotransferases, noninvasive fibrosis tests, serum lipids, glycaemic control and body weight. Adverse events (AEs) were reported in 18 subjects (90%). The most frequently reported AEs were mild/moderate nausea and diarrhea. There were no serious AEs, discontinuations due to AEs, or deaths.

Conclusions: Pegozafermin treatment for 20 weeks had beneficial effects on hepatic and metabolic parameters and was well tolerated in subjects with NASH.

[View Publication](https://drive.google.com/file/d/1LcFlJcyZpKRzPsgB-vM0ceNEuDDzHoZm/view)

[View full post](https://www.pathai.com/publications/clinical-trial-effects-of-pegozafermin-on-the-liver-and-on-metabolic-comorbidities-in-subjects-with-biopsy-confirmed-nonalcoholic-steatohepatitis)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Admin"
  },
  "dateModified" : "2025-07-24T18:45:17.643Z",
  "datePublished" : "2023-08-31T04:00:00Z",
  "headline" : "Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.pathai.com/publications/clinical-trial-effects-of-pegozafermin-on-the-liver-and-on-metabolic-comorbidities-in-subjects-with-biopsy-confirmed-nonalcoholic-steatohepatitis",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "PathAI Publications"
  }
}
```